Bristol Myers Squibb (BMY) Cost of Revenue (2009 - 2026)
Bristol Myers Squibb (BMY) reported Cost of Revenue of $3.4 billion for Q1 2026, up 12.79% year-over-year from $3.0 billion in Q1 2025, and down 16.5% on a QoQ basis from $4.1 billion in Q4 2025.
Bristol Myers Squibb (BMY) has 18 years of Cost of Revenue data on file, last reported at $3.4 billion in Q1 2026.
- Quarterly Cost of Revenue rose 12.79% year-over-year to $3.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.3 billion (up 1.82% YoY) and the FY2025 annual result came in at $13.9 billion, changed 0.23% from the prior year.
- Cost of Revenue slipped to $3.4 billion in Q1 2026 per BMY's latest filing, from $4.1 billion in the prior quarter.
- Across five years, Cost of Revenue topped out at $4.8 billion in Q4 2024 and bottomed at $2.4 billion in Q3 2022.
- The 5-year median for Cost of Revenue is $2.9 billion (2024), against an average of $3.1 billion.
- The widest annual swing landed in 2024, when Cost of Revenue jumped 75.3%; it then dropped 14.86% in 2025.
- Tracing BMY's Cost of Revenue over 5 years: stood at $2.6 billion in 2022, then advanced by 5.86% to $2.7 billion in 2023, then jumped by 75.3% to $4.8 billion in 2024, then decreased by 14.86% to $4.1 billion in 2025, then slipped by 16.5% to $3.4 billion in 2026.
- Per Business Quant, the three latest BMY Cost of Revenue figures stand at $3.4 billion (Q1 2026), $4.1 billion (Q4 2025), and $3.4 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 3.58 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 8.11 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 4.22 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 4.20 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 2.74 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 1.45 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 3.55 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 3.42 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.42 Bn |
| Mar 31, 2026 | 3.42 Bn |
| Dec 31, 2025 | 4.10 Bn |
| Dec 31, 2025 | 4.10 Bn |
| Sep 30, 2025 | 3.44 Bn |
| Sep 30, 2025 | 3.44 Bn |
| Jun 30, 2025 | 3.37 Bn |
| Jun 30, 2025 | 3.37 Bn |
| Mar 31, 2025 | 3.03 Bn |
| Mar 31, 2025 | 3.03 Bn |
| Dec 31, 2024 | 4.81 Bn |
| Dec 31, 2024 | 4.81 Bn |
| Sep 30, 2024 | 2.96 Bn |
| Sep 30, 2024 | 2.96 Bn |
| Jun 30, 2024 | 3.27 Bn |
| Jun 30, 2024 | 3.27 Bn |
| Mar 31, 2024 | 2.93 Bn |
| Mar 31, 2024 | 2.93 Bn |
| Dec 31, 2023 | 2.75 Bn |
| Dec 31, 2023 | 2.75 Bn |
| Sep 30, 2023 | 2.51 Bn |
| Sep 30, 2023 | 2.51 Bn |
| Jun 30, 2023 | 2.88 Bn |
| Jun 30, 2023 | 2.88 Bn |
| Mar 31, 2023 | 2.57 Bn |
| Mar 31, 2023 | 2.57 Bn |
| Dec 31, 2022 | 2.59 Bn |
| Dec 31, 2022 | 2.59 Bn |
| Sep 30, 2022 | 2.35 Bn |
| Sep 30, 2022 | 2.35 Bn |
| Jun 30, 2022 | 2.72 Bn |
| Jun 30, 2022 | 2.72 Bn |
| Mar 31, 2022 | 2.47 Bn |
| Mar 31, 2022 | 2.47 Bn |
| Dec 31, 2021 | 2.36 Bn |
| Dec 31, 2021 | 2.36 Bn |
| Sep 30, 2021 | 2.29 Bn |
| Sep 30, 2021 | 2.29 Bn |
| Jun 30, 2021 | 2.45 Bn |
| Jun 30, 2021 | 2.45 Bn |
| Mar 31, 2021 | 2.84 Bn |
| Mar 31, 2021 | 2.84 Bn |
| Dec 31, 2020 | 2.91 Bn |
| Dec 31, 2020 | 2.91 Bn |
| Sep 30, 2020 | 2.50 Bn |
| Sep 30, 2020 | 2.50 Bn |
| Jun 30, 2020 | 2.70 Bn |
| Jun 30, 2020 | 2.70 Bn |
| Mar 31, 2020 | 3.66 Bn |
| Mar 31, 2020 | 3.66 Bn |
| Dec 31, 2019 | 2.49 Bn |
| Dec 31, 2019 | 2.49 Bn |
| Sep 30, 2019 | 1.79 Bn |
| Sep 30, 2019 | 1.79 Bn |
| Jun 30, 2019 | 1.97 Bn |
| Jun 30, 2019 | 1.97 Bn |
| Mar 31, 2019 | 1.82 Bn |
| Mar 31, 2019 | 1.82 Bn |
| Dec 31, 2018 | 1.61 Bn |
| Dec 31, 2018 | 1.61 Bn |
| Sep 30, 2018 | 1.65 Bn |
| Sep 30, 2018 | 1.65 Bn |
| Jun 30, 2018 | 1.63 Bn |
| Jun 30, 2018 | 1.63 Bn |
| Mar 31, 2018 | 1.58 Bn |
| Mar 31, 2018 | 1.58 Bn |
| Dec 31, 2017 | 1.60 Bn |
| Dec 31, 2017 | 1.60 Bn |
| Sep 30, 2017 | 1.58 Bn |
| Sep 30, 2017 | 1.58 Bn |
| Jun 30, 2017 | 1.57 Bn |
| Jun 30, 2017 | 1.57 Bn |
| Mar 31, 2017 | 1.27 Bn |
| Mar 31, 2017 | 1.27 Bn |
| Dec 31, 2016 | 1.41 Bn |
| Dec 31, 2016 | 1.41 Bn |
| Sep 30, 2016 | 1.31 Bn |
| Sep 30, 2016 | 1.31 Bn |
| Jun 30, 2016 | 1.21 Bn |
| Jun 30, 2016 | 1.21 Bn |
| Mar 31, 2016 | 1.05 Bn |
| Mar 31, 2016 | 1.05 Bn |
| Dec 31, 2015 | 952.00 Mn |
| Dec 31, 2015 | 952.00 Mn |
| Sep 30, 2015 | 1.10 Bn |
| Sep 30, 2015 | 1.10 Bn |
| Jun 30, 2015 | 1.01 Bn |
| Jun 30, 2015 | 1.01 Bn |
| Mar 31, 2015 | 847.00 Mn |
| Mar 31, 2015 | 847.00 Mn |
| Dec 31, 2014 | 966.00 Mn |
| Dec 31, 2014 | 966.00 Mn |
| Sep 30, 2014 | 1.01 Bn |
| Sep 30, 2014 | 1.01 Bn |
| Jun 30, 2014 | 991.00 Mn |
| Jun 30, 2014 | 991.00 Mn |
| Mar 31, 2014 | 968.00 Mn |
| Mar 31, 2014 | 968.00 Mn |
| Dec 31, 2013 | 1.27 Bn |
| Dec 31, 2013 | 1.27 Bn |
| Sep 30, 2013 | 1.18 Bn |
| Sep 30, 2013 | 1.18 Bn |
| Jun 30, 2013 | 1.11 Bn |
| Jun 30, 2013 | 1.11 Bn |
| Mar 31, 2013 | 1.06 Bn |
| Mar 31, 2013 | 1.06 Bn |
| Dec 31, 2012 | 1.08 Bn |
| Dec 31, 2012 | 1.08 Bn |
| Sep 30, 2012 | 987.00 Mn |
| Sep 30, 2012 | 987.00 Mn |
| Jun 30, 2012 | 1.25 Bn |
| Jun 30, 2012 | 1.25 Bn |
| Mar 31, 2012 | 1.30 Bn |
| Mar 31, 2012 | 1.30 Bn |
| Dec 31, 2011 | 1.37 Bn |
| Dec 31, 2011 | 1.37 Bn |
| Sep 30, 2011 | 1.41 Bn |
| Sep 30, 2011 | 1.41 Bn |
| Jun 30, 2011 | 1.48 Bn |
| Jun 30, 2011 | 1.48 Bn |
| Mar 31, 2011 | 1.34 Bn |
| Mar 31, 2011 | 1.34 Bn |
| Dec 31, 2010 | 1.41 Bn |
| Dec 31, 2010 | 1.41 Bn |
| Sep 30, 2010 | 1.28 Bn |
| Sep 30, 2010 | 1.28 Bn |
| Jun 30, 2010 | 1.28 Bn |
| Jun 30, 2010 | 1.28 Bn |
| Mar 31, 2010 | 1.31 Bn |
| Mar 31, 2010 | 1.31 Bn |
| Dec 31, 2009 | 1.43 Bn |
| Dec 31, 2009 | 1.43 Bn |
| Sep 30, 2009 | 1.32 Bn |
| Sep 30, 2009 | 1.32 Bn |
| Jun 30, 2009 | 1.23 Bn |
| Jun 30, 2009 | 1.23 Bn |
| Mar 31, 2009 | 1.17 Bn |
| Mar 31, 2009 | 1.17 Bn |